The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome

Decitabine is approved for the treatment of MDS, but resistance to this agent is common. To determine the mechanisms underlying decitabine resistance, we measured the mRNA expression of metabolism (hENT1, DCK, CDA) and apoptosis (BCL2L10) genes and found that the hENT1 mRNA level was significantly higher in response compared with non-response patients (P = 0.004). Furthermore, the DCK level was significantly reduced for relapse (P = 0.012) compared with those with continued marrow CR (P = 0.222). These findings indicate that the decitabine metabolic pathway affects its therapeutic effects, lower hENT1 expression may induce primary resistance and down-regulated DCK expression may be related to secondary resistance.